Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buccheri, G.
Right arrow Articles by Ferrigno, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buccheri, G.
Right arrow Articles by Ferrigno, D.

Chest, Vol 101, 1287-1292, Copyright © 1992 by American College of Chest Physicians

ARTICLES

Prognostic value of the tissue polypeptide antigen in lung cancer

G Buccheri and D Ferrigno
Division of Pneumology, A. Carle Hospital of Chest Diseases, Cuneo, Italy.

The prognostic impact of TPA was evaluated by assaying the marker in the serum of 563 patients with a newly diagnosed bronchogenic carcinoma. The group included patients with squamous cell cancers and others with tumors of diverse or undefined histologies. Raised levels of TPA were clearly associated with a shortened survival, even adjusting for the stage of disease. A Cox's proportional hazards regression analysis, incorporating all major prognostic factors, selected TPA as an independent survival predictor. In the regression model, however, TPA was less important than disease extent, KPS and weight loss. Another multivariate analysis was made in a subgroup of 121 patients who, because of poor KPS or advanced age, had undergone a limited staging workup; TPA came out as the first most important factor. This study shows that TPA is an important prognostic factor and that it should be included among laboratory data evaluated in lung cancer studies.


This article has been cited by other articles:


Home page
 ChestHome page
G. Buccheri, P. Torchio, and D. Ferrigno
Clinical Equivalence of Two Cytokeratin Markers in Non-small Cell Lung Cancer: A Study of Tissue Polypeptide Antigen and Cytokeratin 19 Fragments
Chest, August 1, 2003; 124(2): 622 - 632.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
G. Buccheri and D. Ferrigno
Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: A study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 891 - 899.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Chest Physicians.